High Serum Insulin-Like Growth Factor Binding Protein-1 is Associated with Increased Cardiovascular Mortality in Elderly Men

M. Harrela; Q. Qiao; R. Koistinen; J. Tuomilehto; A. Nissinen; M. Seppälä; P. Leinonen

doi:10.1055/s-2002-23198

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2002; 34(3): 144-149
DOI: 10.1055/s-2002-23198

Original Clinical

High Serum Insulin-Like Growth Factor Binding Protein-1 is Associated with Increased Cardiovascular Mortality in Elderly Men

M. Harrela ¹ , Q. Qiao ² , R. Koistinen ¹ , J. Tuomilehto ² , A. Nissinen ³ , M. Seppälä ¹ , P. Leinonen ¹

¹Department of Obstetrics and Gynecology, Helsinki University Central Hospital
²Diabetes and Genetic Epidemiology Unit, Department of Epidemiology and Health Promotion and Department of Environmental Epidemiology, National Public Health Institute, Helsinki, Finland
³Department of Community Medicine and Family Practice, University of Kuopio, Kuopio, Finland

Abstract

Insulin-like growth factor binding protein-1 (IGFBP-1) has been implicated in the development of cardiovascular disease, but it is not known whether IGFBP-1 is related to cardiovascular mortality. We examined the relation of circulating IGFBP-1 to death from coronary heart disease, cardiovascular disease, and all causes in a cohort study consisting of 622 men aged 65 - 84 years, at baseline in 1984. Fasting serum IGFBP-1 and other risk factors were measured in 1984 and 1989. Cardiovascular events for those who died between 1984 and 1995 were analyzed, and cardiovascular diagnoses were coded centrally according to standardized procedures. Of the 622 men, 358 died between 1984 and 1995; 160 deaths were due to cardiovascular causes, 113 of which were coronary deaths. High fasting serum IGFBP-1 concentration (> 75 percentile) in 1984 was associated with increased five-year total mortality (OR 2.05, 95 % CI 1.41 - 2.99; p < 0.0002), cardiovascular mortality (OR 2.20, 95 % CI 1.37 - 3.50; p < 0.0009) and coronary heart disease mortality (OR 2.29, 95 % CI 1.35 - 3.88; p < 0.002). After adjustment for age, high serum IGFBP-1 concentrations still carried an increased risk of total mortality due to (OR 1.73, 95 % CI 1.16 - 2.59; p < 0.007), cardiovascular (OR 1.91 95 % CI 1.18 - 3.09; p < 0.008) and coronary heart disease (OR 2.02. 95 % CI 1.18 - 3.47; p < 0.01). In conclusion, high fasting serum IGFBP-1 is related to increased five-year total and cardiovascular mortality in elderly men.

Key words

Aging - Cardiovascular Disease - Coronary Heart Disease - Insulin-Like Growth Factor Binding Protein-1 - Insulin-Like Growth Factor-I

Full Text

References

1 Lindberg O, Tilvis R, Strandberg T, Valvanne J, Sairanen S, Ehnholm C, Tuomilehto J. Impacts of components of the metabolic syndrome on health status and survival in an aged population. Eur J Epidemiol. 1997; 13 429-434
2 Mykkänen L, Laakso M, Pyörälä K. High plasma insulin levels is associated with coronary artery disease in the elderly. Am J Epidemiol. 1993; 137 1190-1202
3 Wingard D L, Ferrara A, Barrett-Connor E L. Is insulin really a heart disease risk factor. Diabetes Care. 1995; 18 1299-1304
4 Le Roith D. Insulin-like growth factors. NEJM. 1997; 360 633-640
5 Tsukahara H, Gordienko D V, Tonshoff B, Gelato M C, Goligorsky M S. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994; 45 598-604
6 Muniyappa R, Walsh M F, Rangi J S, Zayas R M, Standley P R, Ram J L, Sowers J R. Insulin-like growth factor I increases vascular smooth muscle nitric oxide production. Life Sci. 1997; 61 925-931
7 Copeland K C, Nair K S. Recombinant human IGF-I increases forearm blood flow. J Clin Endocrinol Metab. 1994; 79 230-232
8 Banskota N K, Taub R, Zellner K, Olsen P, King G L. Characterization of induction of proto-onkogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-I. Diabetes. 1989; 38 123-129
9 Moses A C, Young S CJ, Morrow L A, O’Brien M, Clemmons D R. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 1996; 45 91-100
10 Baxter R C, Martin J L. Binding proteins of the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res. 1989; 1 49-68
11 Suikkari A M, Koivisto V A, Rutanen E M, Yki-Järvinen H, Karonen S L, Seppälä M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab. 1988; 66 266-272
12 Lee P D, Giudice L C, Conover C A, Powell D R. Insulin-like growth factor binding protein-1: Recent findings and new directions. Proc Sox Exp Biol Med. 1997; 216 319-357
13 Yki-Järvinen H, Mäkimattila S, Utriainen T, Rutanen E M. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein-1 in vivo. . J Clin Endocrinol Metab. 1995; 80 3227-3232
14 Gibson J, Westwood M, Young R, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab. 1996; 81 860-863
15 Harrela M, Koistinen R, Tuomilehto J, Nissinen A, Seppälä M. Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men. Ann Med. 2000; 32 424-428
16 Isgaard J, Tivesten , Friberg P, Bengtsson B. The role of the GH/IGF-I axis for cardiac function and structure. Horm Metab Res. 1999; 31 50-54
17 Janssen J A, Stolk R P, Pols H A, Grobbee D E, Lamberts S W. Serum total IGF-I, free IGF-I, and IGFBP-1 levels in an elderly population: Relation to the cardiovascular risk factors and disease. Arterioscl Trom Vas Biol. 1998; 18 277-282
18 Keys A, Aravanis C, Blackburn H, van Buchem F S, Buzina R, Djordjevic B, Dontas A, Finanza F, Karvonen M, Kimura N, Lekos D, Monti M, Puddu V, Taylor H. Epidemiological studies related to coronary heart disease: Characteristics of men aged 40 - 59 in seven countries. Acta Med Scand. 1966; (Suppl 460) 1-392
19 Nissinen A, Kivel S L, Pekkanen J, Tuomilehto J, Kostiainen E, Piippo H, Lammi U, Kaarsalo E, Romo M, Punsar S, Puska P. Levels of some biological risk indicators among elderly men in Finland. Age Ageing. 1986; 15 203-211
20 Nissinen A, Tervahauta M, Pekkanen J, Kivinen P, Stengård J, Kaarsalo E, Kivelä S L, Väisänen S, Salonen J, Tuomilehto J. Prevalence and change of cardiovascular risk factors among men born 1900 - 1919: The Finnish cohorts of the Seven Countries Study. Age and Ageing. 1993; 22 365-376
21 WHO Study Group on Diabetes Mellitus World Health Organisation .Tech Rep Ser. 727, WHO, Geneva; 1985
22 The expert committee on the diagnosis and classification of diabetes mellitus . Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997; 20 1183-1197
23 Kostner G M. Enzymatic determination of cholesterol in HDL fractions prepared by polyanion precipitation. Clin Chem. 1976; 22 695
24 Rutanen E M, Sepp M, Pietilä R, Bohn H. Placental protein 12 (PP 12): Factors affecting levels in late pregnancy. Placenta. 1984; 5 243-248
25 Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R, Seppälä M. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1 and IGFBP-3. J Clin Invest. 1996; 98 2612-2615
26 Koistinen H, Seppälä M, Koistinen R. Different forms of insulin-like growth factor binding protein-3 in serum and seminal plasma by immunofluorometric assay with monoclonal antibodies. Clin Chem. 1994; 40 531-536
27 WHO .International Classification of Diseases. 8th Revision. Geneva: World Health Organisation; 1967
28 Rutanen E M, Kärkkinen T, Stenman U H, Yki-Järvinen H. Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin. J Clin Endocrinol Metab. 1993; 77 1152-1155
29 Benbassat C A, Maki K C, Unterman T G. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: Relationship to insulin, glucose, IGF and dehydroepiandrosterone sulfate levels and antropometric measures. J Clin Endocrinol Metab. 1997; 82 1484-1491
30 Elgin R G, Busby W H, Clemmons D R. An insulin-like growth factor binding protein enhances the biological response to IGF-I. Proc Natl Acad Sci USA. 1987; 84 3254-3258
31 Jones J I, Gockerman A, Busby W H, Wright G, Clemmons D R. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA. 1993; 90 10553-10557

Maija Harrela, M.D.

Helsinki University Central Hospital

POB 140 · 00290 Helsinki · Finland

Fax: + 358 (9) 47174801

Email: maija.harrela@hus.fi